Novo Nordisk: obesity drugs priority over century-old focus on insulin

Novo's diabetes drug Ozempic and Wegovy are from the class called GLP-1 receptor agonists, and both contain the active ingredient semaglutide, originally developed to help control blood sugar in patients with diabetes. Ozempic is approved for treatment of type 2 diabetes, while Wegovy is approved for weight loss.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Wg0lYnQ
via